Therefore, EGFR is a widely accepted therapeutic target, either using small molecule tyrosine kinase inhibitors (e.g., erlotinib in lung adenocarcinoma) or blocking antibody (e.g., cetuximab in HNSCC). Here, EGFR is linked to head and neck squamous cell carcinoma.